Iradimed (IRMD) Cash from Financing Activities (2013 - 2026)

Iradimed (IRMD) has reported Cash from Financing Activities for 14 consecutive years, with -$2.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 23.66% year-over-year to -$2.8 million in Q2 2026; TTM through Jun 2026 was -$18.5 million, a 108.13% decrease from a year earlier, with the FY2025 full-year figure at -$17.6 million, down 22.77% from the prior year.
• Cash from Financing Activities was -$2.8 million for Q2 2026 at Iradimed, down from -$2.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $52341.0 in Q3 2022 and troughed at -$13.3 million in Q1 2023.
• A 5-year average of -$3.5 million and a median of -$2.2 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 34536.13% in 2022 and soared 71.67% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$198457.0 in 2022, then plunged by 32.32% to -$262590.0 in 2023, then plunged by 820.64% to -$2.4 million in 2024, then slumped by 349.78% to -$10.9 million in 2025, then surged by 74.33% to -$2.8 million in 2026.
• The last three Cash from Financing Activities figures came in at -$2.8 million (Q2 2026), -$2.6 million (Q1 2026), and -$10.9 million (Q4 2025), per Business Quant data.